Wednesday, May 24, 2017 10:24:19 AM
On April 13th, TNTY Provided an Update on Acquisitions, Growth Plans in Specialty Pharmacy, and CBD Related Areas.
• 2 existing sites with plans to add 6 locations in 2017 and up to 10 in 2018.
• They are finishing due diligence on this and expect to close in the next few weeks.
• A timely roll-out of the new stores should double or triple that in 2017. They believe that this group can grow to 16 stores and produce up to 30 million in annualized revenue by the end of 2018.
• The Company is also working on completion of a compounding site in the Southeastern US whose 2016 revenues exceeded 25 million, and a smaller compounder in South Florida that did over $2.5 million in 2016.
• Both sites are profitable and are expected to become the "hubs" in the network, performing a consolidated fill function as well as their role in the compounding products arena.
TNTY just announced the formation of a subsidiary last Thursday as the strategy rollout continues. The individuals who wrote the business plan for the compounding pharmacy roll-up include senior executives who have extensive experience and in-depth knowledge within the not-for-profit space.
True Nature (https://truenaturepharma.com/) is a development stage company focused on consolidation of the compound pharmacy industry through opportunistic acquisitions, starting in the Southeast and then across the US. They expect to be able to rapidly scale this business with a combination of acquisitions, organic growth and creation of economies of scale. The concept is that a national organization can more effectively leverage a broader product line and operational efficiencies.
On May 18th, TNTY Announced a Targeted Community Health Initiative.
• TNTY is rolling out a new initiative aimed at supporting the need for lower cost pharmaceuticals within the medically underserved small town and rural marketplaces.
• The Company intends to form a joint venture for-profit subsidiary; True Nature Community Health, Inc., which will be owned 51% percent by the public company, and 49% by a newly formed not-for-profit entity; The True Nature Community Health Foundation.
Recent MITI News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 05:45:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 07:56:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 02:15:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 06:03:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 09:11:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:41:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 02:23:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2024 09:30:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2024 05:05:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:28:56 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:12:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 08:34:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 09:05:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:00:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/13/2023 08:53:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 07:32:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/19/2023 05:04:40 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/04/2023 04:27:09 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 09/22/2023 06:17:59 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 09/01/2023 08:38:54 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 08/29/2023 09:16:57 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 07/14/2023 08:49:17 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM